GLP1R and diabetic kidney disease: While Farah et al. studied endogenous GLP-1 rather than semaglutide specifically, these mechanisms provide a probable explanation for how GLP-1RA-like semaglutide may influence renal hemodynamics, reduce intraglomerular pressure, and provide an additive renoprotective effect, particularly in the hyperfiltration setting, a characteristic of DKD.